本帖最后由 老马 于 2012-1-13 21:20 编辑 , i/ l1 d' L0 C# e# J
8 g$ ?$ A' B& b; ?7 u: U爱必妥和阿瓦斯丁的比较/ w z! E4 \. J0 x
# f* s- Q: G% w$ P6 k
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" O5 M8 k4 a6 ~( u* s
) ]" B6 n; @9 ?$ @
( u0 ?# {0 s7 i7 O
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% p9 m7 h1 L7 F+ ~' L, T: D
==================================================
: h" p' A% |1 U0 TOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 L3 X* G& p n4 APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: O) c; ~2 I' N# ^0 d
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* x" G; r, r4 [4 k
|
显身卡
6 b1 E! {% K1 ?. h
